Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease

Neuroscience Letters

Volumn 422, Issue 2, 2007, Pages 119-122

  Müller, Thomas ^a   Welnic, Jacub ^a   Woitalla, Dirk ^a   Muhlack, Siegfried ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Exercise; GH; Levodopa; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOMPERIDONE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA;

ADENOHYPOPHYSIS; ADULT; ARTICLE; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN CAPILLARY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENDURANCE; EXERCISE; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; HORMONE METABOLISM; HUMAN; HYPOPHYSIS FUNCTION; HYPOTHALAMUS; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; DRUG SYNERGISM; EXERCISE THERAPY; EXERCISE TOLERANCE; EXERTION; FEMALE; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PITUITARY GLAND, ANTERIOR;

EID: 34447527137     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.06.008     Document Type: Article

References (11)

1. Brownstein M.J. Neuropeptides. In: Siegel G.J., Agranoff B., Albers R.W., and Molinoff P. (Eds). Basic Neurochemistry: Molecular, Cellular, and Medical Aspects (1989), Raven Press, New York 287-309
2. Galea-Debono A., Jenner P., Marsden C.D., Parkes J.D., Tarsy D., and Walters J. Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. J. Neurol. Neurosurg. Psychiatry 40 (1977) 162-167
3. Goetz C.G., Thelen J.A., MacLeod C.M., Carvey P.M., Bartley E.A., and Stebbins G.T. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology 43 (1993) 1040-1042
4. Keranen T., Gordin A., Koulu M., Scheinin M., Antila S., Sundberg S., and Wikberg T. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. J. Neural. Transm. 103 (1996) 729-736
5. Liberman B., Cesar F.P., and Wajchenberg B.L. Human growth hormone (hGH) stimulation tests: the sequential exercise and l-dopa procedure. Clin. Endocrinol. (Oxf.) 10 (1979) 649-654
6. Manetta J., Brun J.F., Maimoun L., Callis A., Prefaut C., and Mercier J. Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E929-E936
7. Meeusen R., Roeykens J., Magnus L., Keizer H., and De Meirleir K. Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist. Int. J. Sports Med. 18 (1997) 571-577
8. Muhlack S., Welnic J., Woitalla D., and Müller T. Exercise improves efficacy of levodopa in patients with Parkinson's disease. Mov. Disord. 22 (2007) 427-430
9. Müller T., Erdmann C., Bremen D., Schmidt W.E., Muhlack S., Woitalla D., and Goetze O. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin. Neuropharmacol. 29 (2006) 61-67
10. Reuter I., Harder S., Engelhardt M., and Baas H. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 15 (2000) 862-868
11. Ziv I., Avraham M., Michaelov Y., Djaldetti R., Dressler R., Zoldan J., and Melamed E. Enhanced fatigue during motor performance in patients with Parkinson's disease. Neurology 51 (1998) 1583-1586